InvoCare (ASX:IVC) share price lower after posting full year loss

The InvoCare Limited (ASX:IVC) share price is on the slide today following the release of its full year results this morning…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The InvoCare Limited (ASX: IVC) share price is trading lower following the release of its full year results.

At the time of writing, the funerals company's shares are down slightly to $11.17.

falling asx share price represented by woman making sad face

Image source: Getty Images

How did InvoCare perform in FY 2020?

It was a very difficult 12 months for InvoCare because of COVID-19 and this was reflected in its financial results.

For the 12 months ended 31 December, the company reported a 4.7% decline in operating revenue to $476.2 million. Management believes this reflects the resilience of its core business and the benefits of diversification in challenging trading conditions.

Unfortunately, the company's earnings didn't hold up as well. InvoCare reported a 29% decline in operating earnings before interest, tax, depreciation and amortisation (EBITDA) to $102.6 million.

The company explained that employee costs (with no JobKeeper support), the fixed cost nature of its facilities, and the previously announced $7 million impact of significant operating items weighed on its operating profit result.

On the bottom line, the company reported a loss after tax of $9.2 million. This partly reflects the impact of non-cash movements in the Prepaid Funeral business' funds under management (FUM).

Despite this loss, the company declared a fully franked final dividend of 7 cents per share. This brought its full year dividend to 12.5 cents per share, which is down 70% from 41 cents per share in FY 2019.

Management commentary

InvoCare's new CEO, Mr Olivier Chretien, said: "While the Group's financial results have been put under pressure in 2020, it is pleasing to see how resilient the business and our people have been."

"I want to thank our dedicated employees who have continued to provide exemplary service despite multiple disruptions. They have provided safe environments and leveraged technology to ensure our client families were able to continue to celebrate and farewell their loved ones in whatever form that took."

Outlook

InvoCare advised that it remains cautious in its outlook. It notes that short term market conditions are still being impacted by COVID restrictions and the timing and extent of the unwind of related impacts remains hard to predict.

Nevertheless, it feels confident about the long-term potential of the business,. It expects its future growth to be supported by population and ageing trends in its markets. Management has also initiated an operating model and cost efficiency review to further strengthen the business' foundations.

Mr Chretien commented: "I am energised by the potential of our businesses. We have an experienced team, strong national and local brands, a modernised asset base and leading market positions. I see many opportunities to leverage and optimise our foundations to meet the evolving needs of our client families and communities with an expanding, omni-channel, value proposition."

"We can also extend our industry leadership through increased focus on talent, safety, sustainability, digital, innovation and proactive stakeholder management. I look forward to setting out our strategic plan for the next 5 years at our inaugural Investor Day to be held in May," he concluded.

Following today's decline, the InvoCare share price is down 23% over the last 12 months.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended InvoCare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

Time to sell written on a clock.
Broker Notes

Sell alert! Why this expert is calling time on Magellan and Ramsay Health Care shares

A leading expert forecasts growing headwinds for Magellan and Ramsay Health Care shares. But why?

Read more »

A beautiful ocean vista is shown with a woman whose back is to the camera holding her arms up in triumph as she stands at the top of a rock feeling thrilled that ASX 200 shares are reaching multi-year high prices today
ASX Share Market News

Record breaker! The ASX 200 just hit a fresh all-time high

Investors just sent the ASX 200 into uncharted territory.

Read more »

Pilot on the phone looking distraught.
Broker Notes

Sell alert! Why this expert is ditching Qantas shares for this ASX 200 defence stock

A leading expert is selling Qantas shares and buying this surging ASX 200 defence stock instead. But why?

Read more »

An old-fashioned news boy stands on a stool and yells through a microphone in an open field.
ASX Share Market News

Why is everyone talking about Domino's, Light & Wonder and BHP shares on Wednesday?

BHP, Light & Wonder, and Domino’s shares are turning heads today. But why?

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

Up 64%, 3 reasons this expert predicts Pro Medicus shares will keep on giving

A leading expert forecasts more outperformance from the surging Pro Medicus share price.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
ASX Share Market News

Earnings preview: can Cochlear shares rebound?

A decade low share price meets a make-or-break result.

Read more »

Business man marking buy on board and underlining it.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Brokers believe that now could be the time to buy these shares.

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Broker Notes

Morgans tips a 600%+ return for this ASX biotech stock

Good clinical study progress has the broker bullish on this company.

Read more »